Loading clinical trials...

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

NCT04630522•Shanghai JMT-Bio Inc.

View on ClinicalTrials.gov

Summary

This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.

Detailed Description

The objective of this trial is to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors. Eligible patients will be randomly assigned to receive JMT103 120mg subcutaneously (SC) every 4 weeks (Q4W), 120mg subcutaneously (SC) every 8 weeks (Q8W) and 180mg subcutaneously (SC) every 8 weeks (Q8W) in a 1:1:1 ratio. Patients will receive the treatment until the completion of 48 weeks of treatment, intolerable toxicity, loss to follow-up, withdrawal (patient's decision or investigator's decision), whichever comes first.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Fully informed and signed informed consent.
•2. Male or female, 18 years and older.
•3. Histologically/cytologically confirmed malignant solid tumors.
•4. Radiographic evidence of at least one bone metastasis.
•5. Eligible fertile patients (male and female) must agree to use an effective method of contraception with their partners from the signing of informed consent until at least 6 months after the last treatment.
•6. Adequate organ functions.
•7. Albumin-corrected serum calcium ≥ 1 x lower limit of normal (LLN) at screening (calcium supplement is not allowed within 8 hours prior to screening).
•8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
•9. Life expectancy ≥ 6 months

Exclusion Criteria

•1. Previous or present osteomyelitis or osteonecrosis of the jaw; unhealed dental or oral surgery wounds; acute disease of the tooth or jaw requiring oral surgery; and invasive dental surgery planned to be received during the study;
•2. Radiotherapy or orthopaedic surgery is planned for patients during the study;
•3. Known symptomatic brain metastases.
•4. Abnormal bone metabolism (such as Paget's disease, Cushing's syndrome, hyperprolactinemia), rheumatoid arthritis, parathyroid disease
•5. Clinically significant disease (such as uncontrolled diabetes, congestive heart failure, hypertension\>150/90 mmHg).
•6. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection.
•7. Systemic therapy of active bacterial infection or fungal infection within 7 days prior to randomization.
•8. Pregnant or lactating women.
•9. Prior use of antibody against nuclear factor kappa-B (NFκB) ligand (RANKL).
•10. Participated in other clinical studies and received other experimental drugs within 4 weeks prior to randomization.
+5 more criteria

Locations (1)

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

October 31, 2020

Primary Completion Date

March 31, 2023

Completion Date

March 31, 2023

Last Updated

November 9, 2023

Enrollment

295

ACTUAL participants

Conditions

Bone Metastases From Solid Tumors

Interventions

Drug: JMT103- 120 mg SC Q4W

DRUG

Drug: JMT103- 120 mg SC Q8W

DRUG

Drug: JMT103- 180 mg SC Q8W

DRUG

Dietary Supplement: Calcium Dietary Supplement: Vitamin D

DIETARY_SUPPLEMENT